Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Monotherapy with the Capsid Assembly Modulator, ALG-000184, Results in High Viral Suppression Rates in Untreated HBeAg+ and HBeAg- Subjects with Chronic Hepatitis B or Chronic Hepatitis B Virus Infection

Friday, November 15, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the promising results of ALG-000184, a capsid assembly modulator, showing high viral suppression rates in untreated patients with chronic Hepatitis B, both HBeAg+ and HBeAg-. This development highlights the potential of ALG-000184 in improving treatment outcomes for chronic HBV infection.
Price reaction · baseline $19.46 (2024-11-14 close) · hit pre-market · 3 other ALGS headline(s) in the window, move may be shared
day 0 close
-1.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • High viral suppression rates observed in subjects.
  • Effective in both HBeAg+ and HBeAg- patients.
  • Potential for significant impact on chronic HBV treatment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-000184?

ALG-000184 is a capsid assembly modulator designed to treat chronic Hepatitis B.

What were the results of ALG-000184?

The treatment resulted in high viral suppression rates in both HBeAg+ and HBeAg- subjects.

Who were the subjects in the study?

The study involved untreated patients with chronic Hepatitis B infection.

What is the significance of these results?

The results indicate a potential breakthrough in the treatment of chronic HBV infection.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-000184 chronic hepatitis B viral suppression HBeAg+ HBeAg-
Last updated: Nov 15, 2024

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →